Glargine 300 IU/ml (Toujeo) in patients with diabetes mellitus type 1 in a real outpatient practice: clinical features of practical use

• Alexander S. Ametov
• Anna O. Nevolnikova
• Mishra O.A.
• Golubeva L.B.

Abstract

With diabetes mellitus type 1 (DM1), an absolute insulin deficiency is observed in the body due to the destruction of β-cells. Therefore, life-substituting insulin therapy is, to date, the only method for treating patients with this pathology. The leading role in the formation of a stable glycemic profile, first of all, to basal insulin. Despite the obvious advantages of the already existing basal insulin analogs, in many patients with DM1, marked day-to-day differences in glucose levels as well as unpredictable glucose fluctuations within the same day and hypoglycemia are still observed. The article presents a clinical analysis of the use of insu­lin glargine with a concentration of 300 U/ml (Toujeo) in 70 patients with DM1 in real outpatient practice. The important clinical features and control points for the initiation of Toujeo therapy are described in detail, which allows using a new preparation of basal insulin with maximum efficiency.

Keywords:diabetes mellitus type 1, basal insulin preparations, practical application, clinical features, Lantus, glargine, Toujeo

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)